BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 14508361)

  • 1. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. A report of three cases.
    Wood BL; Sabath D; Broudy VC; Raghu G
    Cancer; 1996 Nov; 78(10):2223-8. PubMed ID: 8918418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
    Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
    Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
    Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant lymphoproliferative disorder in a kidney-pancreas transplanted recipient: simultaneous development of clonal lymphoid B-cell proliferation of host and donor origin.
    Heyny-von Haussen R; Klingel K; Riegel W; Kandolf R; Mall G
    Am J Surg Pathol; 2006 Jul; 30(7):900-5. PubMed ID: 16819335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
    Davis JE; Sherritt MA; Bharadwaj M; Morrison LE; Elliott SL; Kear LM; Maddicks-Law J; Kotsimbos T; Gill D; Malouf M; Falk MC; Khanna R; Moss DJ
    Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
    Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA
    Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC; Curtis JL; Szmuszkovicz JR; Horn MV; Ford HR; Woo MS; Wang KS
    J Pediatr Surg; 2008 Dec; 43(12):2174-7. PubMed ID: 19040929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
    Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
    Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
    Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
    Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.